AEON Biopharma(AEON) - 2023 Q4 - Annual Results

Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results – Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from planned interim analysis of ongoing Phase 2 study in chronic migraine are expected to be announced in Q2 2024; On track to announce top-line data from the full study in Q3 2024 – – Announced ...